azathioprine, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, azathioprine

Abdelli MN, Ben Abdallah H, Houissa F, Bouali MR, Khediri MF 2007 Azathioprine for prevention of postoperative recurrence in Crohn's disease. Tunis. Med. 85: 569-572.
Abdo A, Klassen J, Urbanski S, Raber E, Swain MG 2003 Reversible sclerosing cholangitis secondary to cryptosporidiosis in a renal transplant patient. J. Hepatol. 38: 688-691. *
Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T, Garrity J, Goeken JA, Allen NB 2002 Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J. Rheumatol. 29: 309-316.
Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR 2003 Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125: 320-327. *
Aberra FN, Lichtenstein GR 2005 Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment. Pharmacol. Ther. 21: 307-319. *
Achkar JP, Stevens T, Easley K, Brzezinski A, Seidner D, Lashner B 2004 Indicators of clinical response to treatment with 6-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10: 339-345. *
Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R 1998 Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm. Bowel Dis. 4: 276-279. *
Actis GC, Fadda M, David E, Sapino A 2007 Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 7: 13. *
Actis GC, Fadda M, Pellicano R, David E, Rizzetto M, Sapino A 2008 The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis. Biomed. Pharmacother. Jul 9 [Epub ahead of print].
Actis GC, Lagget M, Rizzetto M, Fadda M, Palmo A, Pinna-Pintor M, Morino F 2004 Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med. 95: 65-70.
Actis GC, Pazienza P, Rosina F 2008 Mesalamine for inflammatory bowel disease: recent reappraisals. Inflamm. Allergy Drug Targets 7: 1-5.
Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M 2008 Use of corticosteroids, immunomodulators, and Infliximab at a third-level day-hospital service of gastro-hepatology. Minerva Gastroenterol. Dietol. 54: 239-242.
Actis GC, Pinna-Pintor M 2002 An audit of the immunosuppressive management of ulcerative colitis. A retrospective chart review from a referral Day-Hospital of Gastro-enterology. Minerva Gastroenterol. Dietol. 48: 115-120.
Actis GC, Rossetti S, Rizzetto M, Fadda M, Palmo A 2004 Need for hospital admission in patients with ulcerative colitis during maintenance with azathioprine. Minerva Gastroenterol. Dietol. 50: 97-101.
Agnholt J 2008 Biological therapy as treatment of inflammatory bowel diseases. Ugeskr. Laeger. 170: 2152-2156.
Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM 2005 Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin. Gastroenterol. Hepatol. 3: 1215-1220.
Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, Bernstein RM, Walker MG, Bruce IN 2007 Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 46: 983-988. *
Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R 2006 Risk of postoperative infection in patients with inflammatory bowel disease. Korean J. Gastroenterol. 48: 306-312.
Ahn J, Flamm SL, Flamm SL 2005 Autoimmune hepatitis. Curr. Treat. Options Gastroenterol. 8: 481-492.
Aithal GP, Mansfield JC 2001 Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment. Pharmacol. Ther. 15: 1101-1108. *
Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED 2007 Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum. 57: 837-844. *
Akman SA, Arikan C, Sozen G, Ozturk C, Yagci RV 2006 Infliximab treatment of pediatric refractory Crohn's disease: a case report. Turk. J. Gastroenterol. 17: 133-136. *
Akobeng A, Thomas A 2007 Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD005984. *
Akobeng AK 2008 Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment. Pharmacol. Ther. 27: 11-18. *
Akobeng AK 2008 Crohn's disease: current treatment options. Arch. Dis. Child. 93: 787-792.
Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR 2005 Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig. Liver Dis. 37: 282-297.
Al Shammeri O, Duerksen DR 2008 Celiac crisis in an adult on immunosuppressive therapy. Can. J. Gastroenterol. 22: 574-576.
Al-Khalidi JA, Czaja AJ 2001 Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. Mayo Clin. Proc. 76: 1237-1252. *
Al-Toma A, Verbeek W, Hadithi M, von Blomberg M, Mulder C 2007 Survival in refractory coeliac disease and enteropathy associated T cell lymphoma: retrospective evaluation of single centre experience. Gut 56: 1373-1378.
Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC 2005 Eruptive tufted angiomas in a patient with Crohn's disease. J. Clin. Pathol. 58: 214-216. *
Alarcon-Segovia D, Mayorga-Cortes A, Wolpert E 1970 Primary biliary cirrhosis. Prompt relief of pruritus with azathioprine treatment. JAMA 214: 367-368.
Alexander S, Dowling D 2005 Azathioprine pancreatitis in inflammatory bowel disease and successful subsequent treatment with mercaptopurine. Intern. Med. J. 35: 570-571. *
Alfadhli A, McDonald J, Feagan B 2005 Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459. *
Alfadhli AA, McDonald JW, Feagan BG 2003 Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459. *
Ali M, Duerksen DR 2008 Ulcerative colitis and Sweet's syndrome: a case report and review of the literature. Can. J. Gastroenterol. 22: 296-298.
Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, Bonkovsky HL 2006 Autoimmune hepatitis triggered by statins. J. Clin. Gastroenterol. 40: 757-776 ..
Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF 2005 ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54: 565. *
Almer SH, Hjortswang H, Hindorf U 2008 6-Thioguanine therapy in Crohn's disease - observational data in Swedish patients. Dig. Liver Dis. Sep 15 [Epub ahead of print].
Almoznino G, Ben-Chetrit E 2007 Infliximab for the treatment of resistant oral ulcers in Behcet's disease: a case report and review of the literature. Clin. Exp. Rheumatol. 25: S99-S102.
Alonso A, Bignone ML, Brunzini M, Brunzini R 2006 Ocular autoimmune pemphigoid and cyclosporin A. Allergol. Immunopathol. (Madr.) 34: 113-115.
Alvarez F 2004 Treatment of autoimmune hepatitis: current and future therapies. Curr. Treat. Options Gastroenterol. 7: 413-420.
Alvarez F 2004 Round table: controversies in the treatment of autoimmune liver diseases in children. Cyclosporine indication in �autoimmune hepatitis (AIH)�. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 95-96. *
Alves A, Panis Y, Joly F, Pocard M, Lavergne-Slove A, Bouhnik Y, Valleur P 2004 Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease? Inflamm. Bowel Dis. 10: 491-495. *
Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG 2007 Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 682-688.
Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y 2008 Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. Jul 23 [Epub ahead of print].
Ang YS, Farrell RJ 2006 Risk of lymphoma: inflammatory bowel disease and immunomodulators. Gut 55: 580-581. *
Anglicheau D, Legendre C, Thervet E 2004 Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 78: 311-315.
Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44.
Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M 2005 Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study. Am. J. Gastroenterol. 100: 1370-1375. *
Ansari A, Arenas M, Greenfield S, Morris D, Lindsay J, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J 2008 Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. Jul 1 [Epub ahead of print]. *
Ansari A, Aslam Z, DE Sica A, Smith M, Gilshenan K, Fairbanks L, Marinaki A, Sanderson J, Duley J 2008 The influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment. Pharmacol. Ther. 28: 749-757. *
Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J 2008 Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. Jun 26 [Epub ahead of print]. *
Anstey A, Lear JT 1998 Azathioprine: clinical pharmacology and current indications in autoimmune disorders. BioDrugs 9: 33-47.
Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC 2004 Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J. Clin. Gastroenterol. 38: 805-809.
Aranda R, Horgan K 1998 Immunosuppressive drugs in the treatment of inflammatory bowel disease. Semin. Gastrointest. Dis. 9: 2-9.
Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G 2003 Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig. Liver Dis. 35: 619-627.
Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G 2006 Randomised, controlled trial, of azathioprine and 5-aminosalicylic acid for treatment of steroid-dependent ulcerative colitis. Gut 55: 47-53. *
Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G 2004 Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730-740. *
Ardizzone S, Porro GB 2005 Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission? Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 348-349. *
Aringer M, Graninger WB, Steiner G, Smolen JS 2004 Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50: 3161-3169. *
Aringer M, Smolen JS 2008 Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin. Drug Saf. 7: 411-419.
Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS 2007 Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 56: 274-279. *
Armstrong VW, Shipkova M, von Ahsen N, Oellerich M 2004 Analytic aspects of monitoring therapy with thiopurine medications. Ther. Drug Monit. 26: 220-226.
Arnold C, von Sanden S, Theilacker C, Blum HE 2008 Ulcerous colitis and infection with cytomegalovirus, herpes simplex virus and Clostridium difficile. Z. Gastroenterol. 46: 780-783.
Arnott ID, Watts D, Satsangi J 2003 Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res. 47: 1-10. *
Aronoff JS, Korelitz BI, Sohn N, Ky A, Rajapakse R, Weinstein MA, Cohen FS 2000 Anorectal Crohn's disease: surgical and medical management. BioDrugs 13: 95-105.
Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, Penninckx F, Vermeire S, Rutgeerts P 2004 Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm. Bowel Dis. 10: 73-78. *
Arundel C, Lewis JH 2007 Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254.
Asherson RA, Giampaolo D, Strimling M 2008 A case of adult-onset Satoyoshi syndrome with gastric ulceration and eosinophilic enteritis. Nat. Clin. Pract. Rheumatol. 4: 439-444.
Ashraf VV, Taly AB, Veerendrakumar M, Rao S 2006 Myasthenia gravis in children: a longitudinal study. Acta Neurol. Scand. 114: 119-123. *
Asma SD, Soumaya Y, Kahena J, Raouf DM, Nejib D 2006 Perianal Crohn disease. Dermatol. Online J. 12: 18.
Atreya R, Atreya I, Neurath MF 2006 Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1072: 98-113. *
Au WY, Ma ES, Choy C, Chung LP, Fung TK, Liang R, Kwong YL 2005 Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs. Am. J. Hematol. 81: 5-11. *
Auer IO, Buschmann C, Ziemer E 1978 Immune status in Crohn's disease. 2. Originally unimpaired primary cell mediated immunity in vitro. Gut 19: 618-626. *
Aydogan K, Karadogan SK, Adim SB, Tunali S 2006 Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus. Int. J. Dermatol. 45: 1057-1061. *
Babu TG, Boctor D, Davey A, Bond MC, Jacobson K 2004 Cytomegalovirus-associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J. Pediatr. Gastroenterol. Nutr. 39: 418-421. *
Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P 2004 Management of ulcerative colitis and Crohn's disease. Acta Clin. Belg. 59: 304-314.
Baert FJ, Rutgeerts PJ 2000 Medical therapies for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 2: 446-450.
Bagdi E, Kiss J, Borbenyi Z, Piukovics K, Krenacs L 2008 Refractory sprue - precursor lesion of enteropathy type T-cell lymphoma - a clinicopathological case report. Orv. Hetil. 149: 995-998.
Bahrle S, Szabo G, Stiehl A, Theilmann L, Dengler TJ, Zimmermann R, Kubler W 1998 Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection. J. Heart Lung Transplant. 17: 592-598.
Bajaj JS, Saeian K, Varma RR, Franco J, Knox J F, Podoll J, Emmons J, Levy M, Binion DG 2005 Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am. J. Gastroenterol. 100: 1121-1125. *
Baker DE 2003 Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Rev. Gastroenterol. Disord. 3: 150-157. *
Baker DE 2003 Bioequivalence of azathioprine products. Rev. Gastroenterol. Disord. 3: 219-223. *
Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH 1993 Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 18: 1392-1398.
Baldassano VF Jr 1998 Ocular manifestations of rheumatic diseases. Curr. Opin. Ophthalmol. 9: 85-88.
Baldys-Waligorska A, Kusnierz-Cabala B, Huszno B 2006 A special case of thyroid associated ophthalmopathy in the course of Graves-Basedow disease. Endokrynol. Pol. 57: 536-540.
Banerjee S, Bishop WP 2006 Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center: role of thiopurine methyltransferase and 6-mercaptopurine metabolite measurements. J. Pediatr. Gastroenterol. Nutr. 43: 324-330. *
Banerjee S, Rahhal R, Bishop WP 2006 Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 43: 353-356. *
Bankar RN, Dafe CO, Kohnke A, Babu PS 2006 Ulcerative colitis probably associated with isotretinoin. Indian J. Gastroenterol. 25: 171-172. *
Bao S, Root C, Jagasia S 2007 Type B insulin resistance syndrome associated with systemic lupus erythematosus. Endocr. Pract. 13: 51-55.
Barber CE, Geldenhuys L, Hanly JG 2006 Sustained remission of lupus nephritis. Lupus 15: 94-101.
Bardin T 2004 Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 71: 481-485.
Bargallo A, Carrion S, Domenech E, Arevalo JA, Manosa M, Cabre E, Cabriada JL, Gassull MA 2008 Infectious mononucleosis in patients with inflammatory bowel disease under treatment with azathioprine. Gastroenterol. Hepatol. 31: 289-292.
Barnes BH, Borowitz SM, Saulsbury FT, Hellems M, Sutphen JL 2004 Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J. Pediatr. Gastroenterol. Nutr. 38: 509-512. *
Barta Z, Toth L, Zeher M 2006 Pulse cyclophosphamide therapy for inflammatory bowel disease. World J. Gastroenterol. 12: 1278-1280. *
Bastida Pa G, Nos Mate P, Aguas Peri M, Beltran Niclas B, Rodriguez Sole M, Ponce Garcia J 2007 Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease. Gastroenterol. Hepatol. 30: 511-516.
Baughman RP, Iannuzzi M 2003 Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17: 425-431.
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU 2006 Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. 101: 1048-1056. *
Bebb JR, Scott BB 2004 How effective are the usual treatments for Crohn's disease? Aliment. Pharmacol. Ther. 20: 151-159. *
Bebb JR, Scott BB 2004 How effective are the usual treatments for ulcerative colitis? Aliment. Pharmacol. Ther. 20: 143-149. *
Beckebaum S, Cicinnati V, Broelsch CE 2003 Liver transplantation, rejection and disease recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 55-56. October 15-16. *
Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, Newell KA, Thistlethwaite JR, Baker AL 1998 Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 65: 393-396.
Belda A, Hinojosa J, Serra B, Garcia L, Merino C, Belda A, Moles JR 2004 Systemic candidiasis and infliximab therapy. Gastroenterol. Hepatol. 27: 365-367.
Bellomo-Brandao MA, Costa-Pinto EA, Tommaso AM, Hessel G 2006 Clinical and biochemical features of autoimmune hepatitis in 36 pediatric patients. Arq. Gastroenterol. 43: 45-49. *
Belloni B, Andres C, Ollert M, Ring J, Mempel M 2008 Novel immunological approaches in the treatment of atopic eczema. Curr. Opin. Allergy Clin. Immunol. 8: 423-427.
Belmont HM 2006 Treatment of ANCA-associated systemic vasculitis. Bull. Hosp. Jt. Dis. 64: 60-66. *
Ben Ari Z, Mehta A, Lennard L, Burroughs AK 1995 Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J. Hepatol. 23: 351-354. *
Benazzato L, D'Inca R, Grigoletto F, Perissinotto E, Medici V, Angriman I, Sturniolo GC 2004 Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig. Liver Dis. 36: 461-466.
Bendre SV, Shaddock JG, Dobrovolsky VN, Albertini RJ, Heflich RH 2007 Effect of chronic azathioprine treatment on germ-line transmission of Hprt mutation in mice. Environ. Mol. Mutagen. 48: 744-753.
Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, Menchen L, Martin-Arranz MD, Opio V, Carneros JA, Van-Domselaar M, Mendoza JL, Luna M, Lopez P, Calvo M, Algaba A 2008 Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment. Pharmacol. Ther. 28: 623-628. *
Bernal I, Domenech E, Garcia-Planella E, Marin L, Manosa M, Navarro M, Cabre E, Gassull MA 2006 Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig. Dis. Sci. 51: 2165-2169. *
Bernatsky S, Boivin JF, Joseph L, Gordon C, Urowitz M, Gladman D, Ginzler E, Fortin P, Bae SC, Barr S, Isenberg D, Rahman A, Petri M, Alarcon G, Aranow C, Dooley MA, Rajan R, Senecal JL, Zummer M, Manzi S, Edworthy S, Ramsey-Goldman R, Clarke A 2008 The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann. Rheum. Dis. 67: 74-79.
Bernatsky S, Hudson M, Suissa S 2007 Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46: 1157-1160. *
Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold O, Aadland E, Vatn M, Moum B 2005 Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur. J. Gastroenterol. Hepatol. 17: 1037-1045.
Bernstein CN 2002 Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 4: 513-516.
Bessard G, Hardy G, Chartier A, Stanke-Labesque F 2004 Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine. Therapie 59: 71-75.
Beuers U, Rust C 2005 Overlap syndromes. Semin. Liver Dis. 25: 311-320.
Bezier M, Reguiai Z, Vitry F, Broly F, Bernard P 2008 Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases. Eur. J. Dermatol. 18: 512-517.
Bhaduri S, Jenkinson S, Lewis F 2005 Vulval Crohn's disease - a multi-specialty approach. Int. J. STD AIDS 16: 512-514.
Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benezzato L, Papi C, Meucci G, Riegler G, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F 2006 Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched-pair study. Gut 55: 228-233. *
Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F 2003 Review article: maintenance treatment of Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 31-37.
Biasi D, Caramasch P, Carletto A, Casaril M, Colombari R, Zeminian S, Bambara LM 1997 Sjogren's syndrome associated with autoimmune hepatitis. A case report. Clin. Rheumatol. 16: 409-412.
Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M 2007 Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 91: 319-324. *
Bittar F, Reynaud-Gaubert M, Thomas P, Boniface S, Raoult D, Rolain JM 2008 Acetobacter indonesiensis pneumonia after lung transplant. Emerg. Infect. Dis. 14: 997-998. *
Bitton A 2005 Preventing postoperative recurrence in Crohn's disease with 6-mercaptopurine and azathioprine: approaching the cutting edge. Inflamm. Bowel Dis. 11: 513-514. *
Black M, Mignogna M, Scully C 2005 Pemphigus vulgaris. Oral Dis. 11: 119-130. *
Blasco A, Enrique E, Mateo JA, Castello JV, Ferriols R, Malek T 2004 Positive patch test to azathioprine in inflammatory bowel disease. Allergy 59: 368-369. *
Bleday R, Lee E, Jessurun J, Heine J, Wong WD 1993 Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis. Colon Rectum 36: 908-912.
Bloomfeld RS, Onken JE 2003 Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment. Pharmacol. Ther. 17: 69-73. *
Blumenstein I, Bock H, Weber C, Rambow A, Tacke W, Kihn R, Pfaff R, Orlemann S, Schaeffer R, Schroder O, DignaB A, Hartmann F, Stein J 2008 Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: a multicenter, prospective, internet-based study. Inflamm. Bowel Dis. 14: 53-60.
Boberg KM, Schrumpf E 2004 Prognosis of autoimmune liver diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 81. *
Bodger K 2005 Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 23: 875-888.
Bogaard HJ, Erkelens GW, Faber WR, de Vries PJ 2004 Cutaneous nocardiosis as an opportunistic infection. Ned. Tijdschr. Geneeskd. 148: 533-536.
Bogdanos D, Vergani D, Mieli-Vergani G 2004 Overlap syndromes from pediatrics to adulthood. J. Gastroenterol. Hepatol. 19: S284-S286. *
Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF; Getaid 2003 Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 18: 401-408. *
Bondeson J, Veress B, Lindroth Y, Lindgren S 1998 Polymyositis associated with asymptomatic primary biliary cirrhosis. Clin. Exp. Rheumatol. 16: 172-174.
Boonsrirat U, Angsuthum S, Vannaprasaht S, Kongpunvijit J, Hirankarn N, Tassaneeyakul W, Avihingsanon Y 2008 Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. Lupus 17: 132-134.
Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S 2004 Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 36: 342-347.
Bossuyt P, Vergauwe P, Inderadjaja N, Vermeire S 2007 Azathioprine induced colitis: a case report and review of the literature. Acta Gastroenterol. Belg. 70: 302-305.
Botha JF, Spearman CW, Millar AJ, Michell L, Gordon P, Lopez T, Butt A, Thomas J, McCulloch M, James M, Kirsch RE, Terblanche J, Kahn D 2000 Ten years of liver transplantation at Groote Schuur Hospital. S. Afr. Med. J. 90: 880-883.
Boulton-Jones JR, Pritchard K, Mahmoud AA 2000 The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment. Pharmacol. Ther. 14: 1561-1565. *
Boumpas DT, Sidiropoulos P, Bertsias G 2005 Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? Nat. Clin. Pract. Rheumatol. 1: 22-30. *
Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL 2005 A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 11: 833-839. *
Bovenschen HJ, Tjioe M, Vermaat H, Hoop D, Witteman BM, Janssens RW, Stoof TJ, Kerkhof PC 2006 Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br. J. Dermatol. 154: 880-884. *
Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC 2005 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am. J. Hematol. 78: 275-280. *
Brailski Kh, Damianov B 1983 Primary biliary cirrhosis. Vutr. Boles. 22: 27-37.
Brand R 2001 The potential chemoprotective effect of ursodiol. Am. J. Gastroenterol. 96: 1687. *
Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PH 2007 Budesonide in the treatment of refractory celiac disease. Am. J. Gastroenterol. 102: 2265-2269. *
Bray GP, Williams R 1992 Immunointervention in primary biliary cirrhosis: an overview. J. Autoimmun. 5 Suppl. A: 293-300.
Breen DP, Marinaki AM, Arenas M, Hayes PC 2005 Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 11: 826-833. *
Bremner AR, Griffiths DM, Beattie RM 2004 Current therapy of ulcerative colitis in children. Expert Opin. Pharmacother. 5: 37-53.
Bressler B, Sands BE 2006 Review article: medical therapy for fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 24: 1283-1293. *
Breuer GS, Baer A, Dahan D, Nesher G 2006 Lupus-associated pancreatitis. Autoimmun. Rev. 5: 314-318.
Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, Murch SH, Thomson MA, Walker-Smith JA, Lindley KJ, Milla PJ, Dillon MJ 2006 Systemic vasculitis: a cause of indeterminate intestinal inflammation. J. Pediatr. Gastroenterol. Nutr. 42: 405-415. *
Brookes MJ, Green JR 2004 Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64: 1069-1089.
Broome U 2003 Autoimmune hepatitis and overlap syndromes. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 38-39. September 12 - 13. *
Broughton SS, Meyerhoff WE, Cohen SB 2004 Immune-mediated inner ear disease: 10-year experience. Semin. Arthritis Rheum. 34: 544-548. *
Brown SJ, Mayer L 2007 The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102: 2058-2069. *
Brunetti L, Desantis ER 2008 Treatment of viral myocarditis caused by coxsackievirus B. Am. J. Health Syst. Pharm. 65: 132-137.
Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, Derfler K, Graninger W, Kalhs P, Machold K 2002 Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report. Arthritis Rheum. 46: 1580-1584. *
Brunt EM, Di Bisceglie AM 2004 Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis. Hum. Pathol. 35: 509-512.
Brustolim D, Ribeiro-Dos-Santos R, Kast RE, Altschuler EL, Soares MB 2006 A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6: 903-907.
Brydak-Godowska J, Moneta-Wielgos J, Pauk-Domanska M, Drobecka-Brydak E, Samsel A, Kecik M, Kowalewski C, Mackiewicz W, Kecik D 2005 Diagnostics and farmacological treatment of ocular cicatrical pemphigoid. Klin. Oczna. 107: 725-727.
Brynskov J, Feagan BG, Jewell D, McDonald JWD, Stange EF 2004 Cyclosporine for maintenance of remission in Crohn�s disease. Cochrane Database Syst. Rev. 2: CD004377. *
Buchel E, Van Steenbergen W, Nevens F, Fevery J 2002 Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am. J. Gastroenterol. 97: 3160-3165. *
Buller HA 1997 Problems in diagnosis of IBD in children. Neth. J. Med. 50: S8-S11.
Buning C, Lochs H 2006 Conventional therapy for Crohn's disease. World J. Gastroenterol. 12: 4794-4806. *
Bunte C, Popp-Habeler J, Mischer P, Tuppy H, Haidenthaler A, Knoflach P, Kirchgatterer A 2008 Concomitant manifestation of pyoderma gangrenosum and colorectal carcinoma. Scand. J. Gastroenterol. 43: 756-758.
Burak KW, Angulo P, Lindor KD 2003 Is there a role for liver biopsy in primary sclerosing cholangitis? Am. J. Gastroenterol. 98: 1155-1158. *
Buster EH, van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA 2008 Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur. J. Gastroenterol. Hepatol. 20: 68-72.
Cadahia V, Rodrigo L, Fuentes D, Riestra S, De Francisco R, Fernandez M 2005 Celiac disease (CD), ulcerative colitis (UC), and primary sclerosing cholangitis (PSC) in one patient: a family study. Rev. Esp. Enferm. Dig. 97: 907-913. *
Cagatay AA, Taranoglu O, Alpay N, Tufan F, Karadeniz A, Kapmaz M, Buyukbabani N 2008 Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report. Mycoses 51: 81-82.
Cagnard B, Tosoni-Verlingue D, Tribut O, Moizard C, Bridoux-Henno L, Delaperriere N, Bentue-Ferrer D, Dabadie A 2007 Advantages of different dosages of active metabolites in the follow-up of azathioprine treatment for Crohn disease. Arch. Pediatr. 13 Suppl. 1: S67-S68.
Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejon A, Vergara M, Campo R, Brullet E 2006 Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 692-696. *
Campbell S, Ghosh S 2003 Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig. Liver Dis. 35: 546-551.
Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Wright F, Kam I 2008 Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 14: 1281-1286.
Candia L, Marquez J, Espinoza LR 2005 Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin. Arthritis Rheum. 35: 49-56. *
Candinas D, Gunson BK, Nightingale P, Hubscher S, McMaster P, Neuberger JM 1995 Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet 346: 1117-1121.
Cannioto Z, Berti I, Martelossi S, Bruno I, Giurici N, Crovella S, Ventura A 2008 IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur. J. Pediatr. Jun 11 [Epub ahead of print].
Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M 2005 Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Dig. Liver Dis. 37: 407-417.
Cara Terribas CJ, Gonzalez Guijarro L 2002 Hypomethylation and multiple sclerosis, the susceptibility factor? Neurologia 17: 132-135.
Carbone J, Escudero A, Mayayo M, Ballesteros M, Perez-Corral A, Sanchez-Ramon S, Sarmiento E, Micheloud D, Fernandez-Cruz E 2005 Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. Ann. N. Y. Acad. Sci. 1051: 666-671.
Carithers RL Jr 2003 Primary biliary cirrhosis: specific treatment. Clin. Liver Dis. 7: 923-939.
Carter MJ, Lobo AJ, Travis SP 2004 Guidelines for the management of inflammatory bowel disease in adults. Gut 53 Suppl. 5: V1-V16. *
Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR 2007 Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm. Bowel Dis. 13: 1395-1400.
Cassinotti A, Massari A, Ferrara E, Greco S, Bosani M, Ardizzone S, Bianchi Porro G 2007 New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur. J. Clin. Pharmacol. 63: 875-878.
Castro B, Crespo J, Garcia-Suarez C, Fabrega E, Casafont F, Pons-Romero F 2004 Triple immunosuppressive therapy in the treatment of severe ulcerative colitis. Gastroenterol. Hepatol. 27: 1-5.
Cauza E, Dunky A 2006 Psoriatic arthritis. Wien. Med. Wochenschr. 156: 587-595.
Cavailhes A, Ingen-Housz-Oro S, Djennane S, Rafaa M, Fiszenson-Albala F, Weber N, Sigal-Grinberg M 2007 Occurrence of psoriasis in a patient presenting Shulman fasciitis treated with infliximab. Ann. Dermatol. Venereol. 134: 363-367.
Cazanave C, Rakotondravelo S, Morlat P, Blanco P, Bonnet F, Beylot J 2006 Autoimmune hepatitis in a HIV-HCV co-infected patient: diagnostic and therapeutic difficulties. Rev. Med. Interne. 27: 414-419.
Cha JM, Kim HJ 2008 The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J. Gastroenterol. 51: 319-322.
Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL 2007 Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can. Fam. Physician 53: 409-412.
Chan TM 2005 Lupus nephritis: induction therapy. Lupus 14 Suppl. 1: s27-s32.
Chan TM 2007 Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis. Arthritis Rheum. 56: 702-704. *
Chande N, Ponich T, Gregor J 2005 A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can. J. Gastroenterol. 19: 553-558.
Chang HK 2005 Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J. Korean Med. Sci. 20: 883-885. *
Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.
Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S 1980 Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21: 870-877. *
Charpignon C, Beau P 2008 Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Gastroenterol. Clin. Biol. 32: 153-157.
Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B 2005 Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease. Presse. Med. 34: 583-584.
Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF 2007 Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J. Gastroenterol. Hepatol. 22: 268-274. *
Cheikh I, Said Y, Chaabouni H, Ouerghi H, Ben Ammar A 2003 Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: therapeutic features in 5 patients. Ann. Med. Interne. (Paris) 154: 7-11.
Chen SC, Cummings OW, Hartley MP, Filomena CA, Cho WK 2006 Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. Dig. Dis. Sci. 51: 952-955. *
Chen W, Gluud C 2005 Bile acids for liver-transplanted patients. Cochrane Database Syst. Rev. 3: CD005442. *
Choi PM, Targan SR 1994 Immunomodulator therapy in inflammatory bowel disease. Dig. Dis. Sci. 39: 1885-1892.
Chon CY, Park JY 2006 Primary biliary cirrhosis. Korean J. Hepatol. 12: 364-372.
Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R 1985 Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89: 1084-1091.
Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K 2008 Azathioprine treatment during lactation. Aliment. Pharmacol. Ther. Aug 30 [Epub ahead of print]. *
Chrzanowska M, Kurzawski M, Drozdzik M, Mazik M, Oko A, Czekalski S 2006 Thiopurine S-methyltransferase phenotype-genotype correlation in hemodialyzed patients. Pharmacol. Rep. 58: 973-978.
Chuang FR, Lin CC, Wang PH, Cheng YF, Hsu KT, Chen YS, Lee CH, Chen CL 2004 Acute renal failure after cadaveric related liver transplantation. Transplant. Proc. 36: 2328-2330. *
Church NI, Pereira SP, Deheragoda MG, Sandanayake N, Amin Z, Lees WR, Gillams A, Rodriguez-Justo M, Novelli M, Seward EW, Hatfield AR, Webster GJ 2007 Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am. J. Gastroenterol. 102: 2417-2425. *
Claudepierre P, Bagot M 2008 Psoriatic arthritis. Ann. Dermatol. Venereol. 135 Suppl. 4: S263-S268.
Cohen RD 2006 Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results? Gastroenterology 130: 607-608. *
Cohen RD 2002 Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505.
Cohen RD, Tsang JF, Hanauer SB 2000 Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. 95: 3469-3477. *
Colbert C, Chavarria A, Berkelhammer C 2007 Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm. Bowel Dis. 13: 1453-1454.
Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ 2004 Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol. 99: 878-883. *
Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS 2007 The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol. Assess. 11: 1-112. *
Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED 2007 Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 56: 1966-1973. *
Connell W, Miller A 1999 Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 21: 311-323.
Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE 1993 Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34: 1081-1085. *
Contreras AM, Monteon FJ, Flores MR, Mendoza-Sanchez F, Ruiz I 2007 Drug-related hepatotoxicity in a renal transplant recipient with long-term survival and hepatitis C. Ann. Hepatol. 6: 70-73. *
Contreras G, Tozman E, Nahar N, Metz D 2005 Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14 Suppl. 1: s33-s38.
Copeland BH, Aramide O, Wehbe S, Fitzgerald SM, Krishnaswamy G 2004 Eosinophilia in a patient with cyclical vomiting: a case report. Clin. Mol. Allergy 2: 7. *
Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP 2005 Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54: 237-241. *
Costantino G, Della Torre A, Lo Presti MA, Caruso R, Mazzon E, Fries W 2008 Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig. Liver Dis. 40: 74-77.
Cottone M, Orlando A, Modesto I 2006 Postoperative maintenance therapy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 22: 377-381.
Crispino P, Pica R, Angelucci E, Consolazio A, Rivera M, Cassieri C, Paoluzi P 2007 Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. Int. J. Colorectal Dis. 22: 553-558. *
Crowe J, Christensen E, Smith M, Cochrane M, Ranek L, Watkinson G, Doniach D, Popper H, Tygstrup N, Williams R 1980 Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology 78: 1005-1010.
Csepregi A, Rocken C, Treiber G, Malfertheiner P 2006 Budesonide induces complete remission in autoimmune hepatitis. World J. Gastroenterol. 12: 1362-1366. *
Csillag C, Borup R, Olsen J, Nielsen FC, Nielsen OH 2007 Treatment response and colonic gene expression in patients with Crohn's disease. Scand. J. Gastroenterol. 42: 834-840. *
Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, Gonzalez T, Lopez S, Garsd A, Alvarez F 2006 Follow-up of children with autoimmune hepatitis treated with cyclosporine. J. Pediatr. Gastroenterol. Nutr. 43: 635-639. *
Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, De'Angelis GL, Federici T 2008 Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig. Liver Dis. 40 Suppl. 2: S260-S264.
Cuffari C 2006 Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. 58: 139-157.
Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM 2004 Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2: 410-417. *
Cuffari C, Hunt S, Bayless T 2001 Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48: 642-646. *
Cuffari C, Hunt S, Bayless TM 2000 Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. Ther. 14: 1009-1014. *
Cuffari C, Li DY, Mahoney J, Barnes Y, Bayless TM 2004 Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig. Dis. Sci. 49: 133-137. *
Cukovic-Cavka S 2004 Diffuse jejunoileitis in an adolescent. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 69. May 7-8. *
Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW 2008 High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective? J. Hepatol. 48: 792-800. *
Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP 2005 Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther. 21: 385-389. *
Czaja AJ 2008 Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 25: 219-239.
Czaja AJ 2008 Safety issues in the management of autoimmune hepatitis. Expert Opin. Drug Saf. 7: 319-333.
Czaja AJ 2007 Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262.
Czaja AJ 1999 Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 57: 49-68.
Czaja AJ 1990 Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 11: 1044-1049.
Czaja AJ 2004 Autoimmune liver disease. Curr. Opin. Gastroenterol. 20: 231-240.
Czaja AJ 2002 Treatment of autoimmune hepatitis. Semin. Liver Dis. 22: 365-378. *
Czaja AJ 1999 Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70.
Czaja AJ 1996 Diagnosis and therapy of autoimmune liver disease. Med. Clin. North Am. 80: 973-994.
Czaja AJ 2002 Treatment strategies in autoimmune hepatitis. Clin. Liver Dis. 6: 511-536.
Czaja AJ 2007 Autoimmune liver disease and rheumatic manifestations. Curr. Opin. Rheumatol. 19: 74-80.
Czaja AJ 2002 Emerging treatments for autoimmune hepatitis. Curr. Drug Targets Inflamm. Allergy 1: 317-326.
Czaja AJ 2006 Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J. Hepatol. 44: 251-252. *
Czaja AJ, Carpenter HA 2006 Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig. Dis. Sci. 51: 968-975. *
Czaja AJ, Wang KK, Shiels MT, Katzmann JA 1993 Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses. J. Hepatol. 17: 180-186.
D'Haens G 2004 Optimizing the use of current drugs in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 65. May 7-8. *
D�Haens G 2005 Pratical use of steroids in IBD. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 30. *
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenk�hn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P 2008 Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667. *
D'Haens G, Daperno M 2002 Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 4: 506-512.
D'Haens G, Hlavaty T 2004 Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 6: 496-505.
D'Haens G, Rutgeerts P 1999 Postoperative recurrence of Crohn's disease: pathophysiology and prevention. Inflamm. Bowel Dis. 5: 295-303. *
D'Haens G, Suenaert P, Westhovens R, Rutgeerts P 1998 Severe knee pain as the single symptom of CMV infection in acute ulcerative colitis treated with cyclosporine. Inflamm. Bowel Dis. 4: 27-28.
D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P 2008 Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology Jul 16 [Epub ahead of print]. *
D'halluin PN, Tribut O, Branger B, Lebreton C, Bretagne JF, Bentue-Ferrer D, Heresbach D 2005 RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. Gastroenterol. Clin. Biol. 29: 1264-1269.
D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR 2005 An unusual form of autoimmune hepatitis in young Somalian men. Liver Int. 25: 325-330. *
Damergis JA, Chee K, Amitai A 2008 Otogenic pneumococcal meningitis with pneumocephalus. J. Emerg. Med. Jun 30 [Epub ahead of print].
Danalioglu A, Kaymakoglu S, Mungan Z, Karaca C, Demir K, Durakoglu Z, Besisik F, Boztas G, Cakaloglu Y, Okten A 2002 Efficacy of cyclosporin in severe ulcerative colitis attack. Turk. J. Gastroenterol. 13: 130-133. *
Danalioglu A, Kaymakoglu S, Mungan Z, Karaca C, Demir K, Durakoglu Z, Besisik F, Boztas G, Cakaloglu Y, Okyen A 2003 Cyclosporin for severe ulcerative colitis attacks. Hepatogastroenterology 50 Suppl. 2: ccxcviii-ccc.
Daniel F, Cadranel JF, Seksik P, Cazier A, Duong Van Huyen JP, Ziol M, Coutarel P, Loison P, Jian R, Marteau P 2005 Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol. Clin. Biol. 29: 600-603.
Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK 2008 Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig. Dis. Sci. Sep 4 [Epub ahead of print]. *
Davalos M, Roman R, Bustios C, Zumaeta E, Yabar A 2004 Autoimmune hepatitis: clinical forms and related factors to their response to treatment. Rev. Gastroenterol. Peru 24: 305-313.
Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ 2002 Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122: 72-77. *
de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, den Hartog G, Hooymans PM, Makelburg AB, Westerveld BD, Naber AH, Mulder CJ, de Jong DJ 2005 On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J. Gastroenterol. 11: 5540-5544. *
De Boer NK, Graaf P, Wilhelm AJ, Mulder CJ, Bodegraven AA 2005 On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment. Pharmacol. Ther. 22: 447-451. *
de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA 2006 Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am. J. Gastroenterol. 101: 1390-1392. *
de Boer NK, Mulder CJ, van Bodegraven AA 2005 Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth. J. Med. 63: 444-446. *
de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkuhn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ 2006 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 73: 25-31.
de Boer NK, van Bodegraven AA, de Graaf P, van der Hulst RW, Zoetekouw L, van Kuilenburg AB 2008 Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. Ther. Drug Monit. 30: 390-393.
de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ 2007 Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 686-694. *
de Boer NK, Van Elburg RM, Wilhelm AJ, Remmink AJ, Van Vugt JM, Mulder CJ, Van Bodegraven AA 2005 6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand. J. Gastroenterol. 40: 1374-1377. *
de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ 2005 Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur. J. Gastroenterol. Hepatol. 17: 457-461.
de Boer NK, Zondervan PE, Gilissen LP, den Hartog G, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJ 2008 Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver Dis. 40: 108-113.
de Caestecker JS 1997 Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 9: 145-147.
de Fonclare AL, Khosrotehrani K, Aractingi S, Duriez P, Cosnes J, Beaugerie L 2007 Erythema nodosum-like eruption as a manifestation of azathioprine hypersensitivity in patients with inflammatory bowel disease. Arch. Dermatol. 143: 744-748.
De Jesus-Monge WE, Torres EA, Baez VM, De Jesus O, Rivera L, Gonzalez-Keelan C 2004 Crohn's disease associated to chordoma: a case report. P. R. Health Sci. J. 23: 233-236.
de Jong D, Mulder CJ, van Sorge AA 2001 Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut 49: 874. *
de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ 2003 Safety of thiopurines in the treatment of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 239: 69-72. *
De Jong DJ, Goullet M, Naber TH 2004 Side effects of azathioprine in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 16: 207-212.
De La Rue SA, Bickston SJ 2006 Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22: 365-369.
De Ridder L, Van Dieren JM, Van Deventer HJ, Stokkers PC, Van der Woude JC, Van Vuuren AJ, Benninga MA, Escher JC, Hommes DW 2006 Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment. Pharmacol. Ther. 23: 1137-1141. *
De Vos M 2002 Standard and innovative therapy of inflammatory bowel diseases. Clin. Exp. Rheumatol. 20 (6 Suppl. 28): S95-S100.
De-Leon-Bojorge B, Zaltzman-Girsevich S, Ortega-Salgado A, Prieto-Patron A, Cordoba-Cordoba R, Yamazaki-Nakashimada M 2006 Thrombotic microangiopathy involving the gallbladder as an unusual manifestation of systemic lupus erythematosus and antiphospholipid syndrome: case report and review of the literature. World J. Gastroenterol. 12: 7206-7209. *
Decker GA, Loftus EV Jr, Pasha TM, Tremaine WJ, Sandborn WJ 2001 Crohn's disease of the esophagus: clinical features and outcomes. Inflamm. Bowel Dis. 7: 113-119. *
Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W 2003 Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment. Pharmacol. Ther. 18: 1113-1120.
Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, Moser G 2001 Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 121: 1048-1053. *
Demirtas-Ertan G, Rowshani AT, Ten Berge IJ 2006 Azathioprine-induced shock in a patient suffering from undifferentiated erosive oligoarthritis. Neth. J. Med. 64: 124-126. *
Denys BG, Bogaerts Y, Coenegrachts KL, De Vriese AS 2007 Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin. Sci. (Lond.) 112: 281-289. *
Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ 2003 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol. 15: 63-67.
Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW 2006 Review article: thiopurines in inflammatory bowel disease. Aliment. Pharmacol. Ther. 24: 715-729. *
Derijks LJ, van Helden RB, Hommes DW, Stokkers PC 2008 Dosing azathioprine in thiopurine S-methyltransferase deficient inflammatory bowel disease patients. Gut 57: 872.
Dervieux T, Meyer G, Barham R, Matsutani M, Barry M, Boulieu R, Neri B, Seidman E 2005 Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin. Chem. 51: 2074-2084. *
Desar IM, Weemaes CM, van Deuren M, van der Meer JW 2007 Reversible hypogammaglobulinaemia. Neth. J. Med. 65: 381-385. *
Devlin SM, Swain MG, Urbanski SJ, Burak KW 2004 Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can. J. Gastroenterol. 18: 321-326.
Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y 2002 Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment. Pharmacol. Ther. 16: 79-85. *
Dhillon S, Loftus EV 2005 Medical therapy of Crohn's disease. Curr. Treat. Options Gastroenterol. 8: 19-30.
Diamanti A, Basso MS, Gambarara M, Papadatou B, Bracci F, Noto C, Castro M 2008 Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients. Int. J. Colorectal Dis. Sep 17 [Epub ahead of print]. *
Diamanti AP, Rosado MM, Carsetti R, Valesini G 2007 B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun. Rev. 7: 143-148.
Diez M, Sanchez E, Garcia Lopez S, Arroyo MT, Gomollon F 2007 Infliximab therapy in ulcerative colitis: initial experience in two referral centers. Gastroenterol. Hepatol. 30: 449-453.
Dijkstra G, Hospers GA, Kleibeuker JH 2003 Gene therapy with interleukin 10 in Crohn's disease: too early yet. Ned. Tijdschr. Geneeskd. 147: 2153-2156.
Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Muller R, Schwab M 2007 Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther. Drug Monit. 29: 1-5.
Din S, Cochrane CJ, Noble CL, Satsangi J, Arnott ID 2008 Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease. Inflamm. Bowel Dis. 14: 143-145.
Din S, Dahele A, Fennel J, Aitken S, Shand AG, Arnott ID, Satsangi J 2008 Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm. Bowel Dis. 14: 756-762.
Disanti W, Rajapakse RO, Korelitz BI, Panagopoulos G, Bratcher J 2006 Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 1025-1029.
Domenech E 2006 Inflammatory bowel disease: current therapeutic options. Digestion 73 Suppl. 1: 67-76.
Domenech E, Manosa M, Bernal I, Garcia-Planella E, Cabre E, Pinol M, Lorenzo-Zuniga V, Boix J, Gassull MA 2008 Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm. Bowel Dis. 14: 508-513.
Domenech E, Nos P, Papo M, Lopez-San Roman A, Garcia-Planella E, Gassull MA 2005 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand. J. Gastroenterol. 40: 52-55. *
Domenech E, Scala L, Bernal I, Garcia-Planella E, Casalots A, Pinol M, Esteve-Comas M, Cabre E, Boix J, Gassull MA 2004 Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study. Gastroenterol. Hepatol. 27: 563-567.
Domenech E, Vega R, Ojanguren I, Hernandez A, Garcia-Planella E, Bernal I, Rosinach M, Boix J, Cabre E, Gassull MA 2008 Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm. Bowel Dis. 14: 1373-1379.
Dooley MA, Ginzler EM 2006 Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum. Dis. Clin. North Am. 32: 91-102.
Dooley TP, Curto EV, Reddy SP, Davis RL, Lambert GW, Wilborn TW, Elson CO 2004 Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. Inflamm. Bowel Dis. 10: 1-14. *
Dray X, Joly F, Lavergne-Slove A, Treton X, Bouhnik Y, Messing B 2006 A severe but reversible refractory sprue. Gut 55: 1210-1211. *
Dubinsky MC 2003 Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 506-511.
Dubinsky MC 2004 Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin. Gastroenterol. Hepatol. 2: 731-743. *
Dubinsky MC, Fleshner PP 2003 Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200.
Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA 2001 An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis. 7: 181-189. *
Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ 2005 A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100: 2239-2247. *
Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF 2003 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125: 298-303. *
Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA 2002 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122: 904-915. *
Duclos-Vallee JC, Di Martino V, Cazier A, Ballot E, Johanet C, Yamamoto AM, Emile JF, Guettier C, Coutarel P, Cadranel JF 2005 Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids. Gastroenterol. Clin. Biol. 29: 1173-1176.
Duley JA, Florin TH 2005 Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 27: 647-654.
Dunand M, Lalive PH, Vokatch N, Kuntzer T 2007 Myasthenia gravis: treatments and remissions. Rev. Med. Suisse. 3: 1185-1186, 1188-1190.
Dupont B, Dupont C, Justum AM, Piquet MA, Reimund JM 2008 Enteral nutrition in adult Crohn's disease: present status and perspectives. Mol. Nutr. Food Res. 52: 875-884. *
Durazzo M, Premoli A, Morello E 2004 Autoimmune hepatitis: present knowledges. Minerva Med. 95: 1-9.
Duvoux C, Kracht M, Lang P, Vernant JP, Zafrani ES, Dhumeaux D 1991 Nodular regenerative hyperplasia of the liver associated with azathioprine therapy. Gastroenterol. Clin. Biol. 15: 968-973.
Efthimiou P, Georgy S 2006 Pathogenesis and management of adult-onset Still's disease. Semin. Arthritis Rheum. 36: 144-152. *
Efthimiou P, Kontzias A, Ward CM, Ogden NS 2007 Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat. Clin. Pract. Rheumatol. 3: 328-335. *
Efthimiou P, Paik P, Bielory L 2006 Diagnosis and management of adult onset Still's disease. Ann. Rheum. Dis. 65: 564-572. *
Egan LJ 2004 Mechanism of action of established drugs: cyclosporine, methotrexate and others. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 63-64. May 7-8. *
Egan LJ, Derijks LJ, Hommes DW 2006 Pharmacogenomics in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 21-28. *
Eguchi S, Takatsuki M, Hidaka M, Tajima Y, Zen Y, Nakanuma Y, Kanematsu T 2008 De novo autoimmune hepatitis after living donor liver transplantation is unlikely to be related to immunoglobulin subtype 4-related immune disease. J. Gastroenterol. Hepatol. 23: e165-e169. *
Ehmsen L, Marko C, Breidert M 2008 Portal vein hypertension with azathioprine therapy in patients with Crohn's disease - is it a frequent phenomenon? Dtsch. Med. Wochenschr. 133: 950-953.
Eid AJ, Brown RA, Paya CV, Razonable RR 2007 Association between Toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 84: 511-516.
Eisenbach C, Goeggelmann C, Flechtenmacher C, Stremmel W, Encke J 2005 Severe cholestatic hepatitis caused by azathioprine. Immunopharmacol. Immunotoxicol. 27: 77-83.
El-Azhary RA, Brunner KL, Gibson LE 2008 Sweet syndrome as a manifestation of azathioprine hypersensitivity. Mayo Clin. Proc. 83: 1026-1030.
El-Hag K, Dercken HG, Prenzel R, Holzle E 2008 Drug-induced alveolitis associated with infliximab/azathioprine therapy. Pneumologie. 62: 204-208.
El-Sehemy MS, Al-Saaran AM, Baddour NM, Adam AG, Moez PE 2006 Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis. Egypt. J. Immunol. 13: 39-52.
Elliott PR, Moore GT, Bell SJ, Connell WR 2005 Severe recurrent Crohn's disease of the ileocolonic anastomosis disappearing completely with antibacterial therapy. Gut 54: 1818-1819. *
Elsing C, Placke J, Herrmann T 2007 Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease. World J. Gastroenterol. 13: 4646-4648. *
Eriksson P 2005 Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 257: 540-548. *
Eroglu Y, Duzovali O, Kavukcu S, Irken G, Buyukgebiz B 1997 Combination of steroid with azathioprine in treatment of giant cell autoimmune hepatitis. Turk. J. Pediatr. 39: 565-571.
Erzin Y, Cosgun S, Dobrucali A, Tasyurekli M, Erdamar S, Tuncer M 2006 Complicated granulomatous colitis in a patient with Hermansky-Pudlak syndrome, successfully treated with infliximab. Acta Gastroenterol. Belg. 69: 213-216.
Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ 2003 Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm. Bowel Dis. 9: 34-58. *
Etchevers MJ, Aceituno M, Sans M 2008 Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J. Gastroenterol. 14: 5512-5518. *
Evereklioglu C 2005 Current concepts in the etiology and treatment of Behcet disease. Surv. Ophthalmol. 50: 297-350.
Fang W, Yang P 2008 Vogt-Koyanagi-Harada syndrome. Curr. Eye Res. 33: 517-523.
Fargher EA, Eddy C, Newman W, Qasim F, Tricker K, Elliott RA, Payne K 2007 Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8: 1511-1519.
Farhi D, Duriez P, Aractingi S, Cosnes J, Khosrotehrani K 2007 Misleading pustular plaques of the lower limbs during Crohn's disease: two case reports. J. Med. Case Reports 1: 109. *
Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A 2005 Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116: 134-141. *
Feagan BG 2005 Management of perianal and fistulizing disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 37. *
Feagan BG 2003 Maintenance therapy for inflammatory bowel disease. Am. J. Gastroenterol. 98: S6-S17. *
Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ 2005 Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42: 53-62. *
Felizardo M, Gomes A, Sousa M, Teixeira A, Freitas J, Tavares A, Vaz Patto J, Gomes M 2007 Immunosuppression and tuberculosis. Rev. Port. Pneumol. 13: S23-S24.
Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF 2002 Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel Dis. 8: 317-324. *
Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL 1999 Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am. J. Gastroenterol. 94: 241-248. *
Ferrantelli A, Bono L, Tortorici C, Termini R, Giammarresi C, Rotolo U 2005 Treatment of lupus nephritis. G. Ital. Nefrol. 22: S27-33.
Ferreira AR, Roquete ML, Penna FJ, Toppa NH 2002 Autoimmune hepatitis in children and adolescents: clinical study, diagnosis and therapeutic response. J. Pediatr. (Rio. J.) 78: 309-314. *
Ferrero S, Ragni N 2004 Inflammatory bowel disease: management issues during pregnancy. Arch. Gynecol. Obstet. 270: 79-85.
Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W 1998 Mycophenolate mofetil in patients with Crohn's disease. Am. J. Gastroenterol. 93: 2529-2532. *
Fields CL, Robinson JW, Roy TM, Ossorio MA, Byrd RP Jr 1998 Hypersensitivity reaction to azathioprine. South. Med. J. 91: 471-474.
Filik L, Dagli U, Ulker A 2006 C-reactive protein and monitoring the activity of Crohn's disease. Adv. Ther. 23: 655-662.
Filler G, Lepage N 2004 To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr. Nephrol. 19: 962-965.
Firooz A, Ghandi N, Hallaji Z, Chams-Davatchi C, Valikhani M, Karbakhsh Davari M 2008 Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Arch. Dermatol. 144: 1143-1147. *
Flasar MH, Johnson T, Roghmann MC, Cross RK 2008 Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm. Bowel Dis. 14: 13-19.
Fofi C, Nicoletti MC, Onetti-Muda A, Giulio S 2003 Focal segmental glomerulosclerosis with IgA deposits in a patient with ulcerative colitis. G. Ital. Nefrol. 20: 641-644.
Fonseca JE, Reis P, Saraiva F, Crujo C, Baptista A, da Silva JA, Viana Queiroz M 1999 A complex case of hepatitis in a patient with systemic lupus erythematosus. Clin. Rheumatol. 18: 414-416.
Fowkes L, Krishna K, Menon A, Greenslade GL, Dixon AR 2008 Laparoscopic emergency and elective surgery for ulcerative colitis. Colorectal Dis. 10: 373-378. *
Fracchia M, Galatola G, Pera A, Foti M, Tabone M 2008 Acute diarrhea during azathioprine treatment of type I autoimmune hepatitis. Minerva Med. 99: 219-222.
Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH 2003 The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124: 9-17. *
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.
Francolla KA, Altman A, Sylvester FA 2008 Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J. Pediatr. Gastroenterol. Nutr. 47: 193-195.
Freeman HJ, Berean K, Nimmo M 2007 Evolution of collagenous colitis into severe and extensive ulcerative colitis. Can. J. Gastroenterol. 21: 315-318.
Frei P, Fried M, Hungerbuhler V, Rammert C, Rousson V, Kullak-Ublick GA 2006 Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion 73: 40-46.
Friedman S 2007 Medical therapy and birth outcomes in women with Crohn's disease: what should we tell our patients? Am. J. Gastroenterol. 102: 1414-1416.
Friedman S, Marion JF, Scherl E, Rubin PH, Present DH 2001 Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm. Bowel Dis. 7: 1-7. *
Froehlich F, Juillerat P, Felley C, Mottet C, Vader JP, Burnand B, Michetti P, Gonvers JJ 2005 Treatment of postoperative Crohn's disease. Digestion 71: 49-53.
Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ 2007 Maintenance of surgically induced remission of Crohn's disease. Digestion 76: 130-135.
Gaburri D, Chebli JM, Zanine A, Gamonal AC, Gaburri PD 2008 Onychomycosis in inflammatory bowel diseases. J. Eur. Acad. Dermatol. Venereol. 22: 807-812. *
Gambichler T, Reich S, Banasch M, Altmeyer P 2006 Complex extra-intestinal complications of ulcerative colitis in a patient with alpha1-antitrypsin deficiency. Eur. J. Med. Res. 11: 135-138.
Garcia RF, Garcia CE, McMaster P 2000 Chronic rejection of the liver: the role of immunosuppression. BioDrugs 14: 283-297.
Garcia Romero R, Martin de Carpi J, Bernal Cuartas C, Pinillos Pison S, Varea Calderon V 2007 Autoimmune hepatitis in pediatric patients. Rev. Esp. Enferm. Dig. 99: 255-258.
Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, Marcos Andrade Goulart E, Sales Da Cunha A 2008 Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand. J. Gastroenterol. 43: 842-848. *
Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML 2008 Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ 3-fold. Clin. Gastroenterol. Hepatol. 6: 654-660.
Gassert DJ, Garcia H, Tanaka K, Reinus JF 2007 Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig. Dis. Sci. 52: 2433-2437. *
Gearry R, Barclay M, Gardiner S, Zhang M 2003 6-Thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. N. Z. Med. J. 116: U531. *
Gearry RB, Barclay ML 2005 Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20: 1149-1157. *
Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA 2004 Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 13: 563-567. *
Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA 2003 Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18: 395-400. *
Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM 2005 Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern. Med. J. 35: 580-585. *
Gearry RB, Roberts RL, Barclay ML, Kennedy MA 2004 Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14: 779-781.
Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR 2004 Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am. J. Surg. Pathol. 28: 1204-1211.
Gerber NL, Steinberg AD 1976 Clinical use of immunosuppressive drugs: part II. Drugs 11: 90-112.
Getliffe KM, Al Dulaimi D, Martin-Ruiz C, Holder RL, von Zglinicki T, Morris A, Nwokolo CU 2005 Lymphocyte telomere dynamics and telomerase activity in inflammatory bowel disease: effect of drugs and smoking. Aliment. Pharmacol. Ther. 21: 121-131. *
Geubel AP, Baggenstoss AH, Summerskill WH 1976 Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology 71: 444-449.
Ghosh S, Chaudhary R, Carpani M, Playford RJ 2006 Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease? Gut 55: 6-8. *
Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG 2004 Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin. Drug Investig. 24: 479-486.
Gilissen LP, Derijks LJ, Bos LP, Verhoeven HM, Bus PJ, Hooymans PM, Engels LG 2004 Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur. J. Gastroenterol. Hepatol. 16: 705-710.
Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrugger RW, Engels LG 2007 Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig. Liver Dis. 39: 156-159.
Gillett HR, Arnott ID, McIntyre M, Campbell S, Dahele A, Priest M, Jackson R, Ghosh S 2002 Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology 122: 800-805. *
Ginsburg PM, Dassopoulos T 2006 Steroid dependent ulcerative colitis: azathioprine use is finally "evidence-based". Inflamm. Bowel Dis. 12: 921-922. *
Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M 2002 Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment. Pharmacol. Ther. 16 Suppl. 4: 13-19. *
Gionchetti P, Rizzello F, Habal F, Morselli C, Amadini C, Romagnoli R, Campieri M 2003 Standard treatment of ulcerative colitis. Dig. Dis. 21: 157-167.
Girschick HJ, Zimmer C, Klaus G, Darge K, Dick A, Morbach H 2007 Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated? Nat. Clin. Pract. Rheumatol. 3: 733-738. *
Girszyn N, Leport J, Arnaud L, Kahn JE, Piette AM, Bletry O 2007 Crohn's disease affecting only vulvoperineal area. Presse. Med. 36: 1762-1765.
Gisbert JP, Gomollon F 2008 Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am. J. Gastroenterol. 103: 1783-1800. *
Gisbert JP, Gomollon F, Cara C, Luna M, Gonzalez-Lama Y, Pajares JM, Mate J, Guijarro LG 2005 Thiopurine methyltransferase activity in the inflammatory bowel disease. A study on 7046 Spanish patients. Med. Clin. (Barc.) 125: 281-285.
Gisbert JP, Gomollon F, Cara C, Luna M, Gonzalez-Lama Y, Pajares JM, Mate J, Guijarro LG 2007 Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig. Dis. Sci. 52: 1262-1269. *
Gisbert JP, Gonzalez-Guijarro L, Cara C, Pajares JM, Moreno-Otero R 2003 Thiopurine methyltransferase activity in patients with autoimmune hepatitis. Med. Clin. (Barc.) 121: 481-484.
Gisbert JP, Gonzalez-Lama Y, Mate J 2006 Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease. Gastroenterol. Hepatol. 29: 568-583.
Gisbert JP, Gonzalez-Lama Y, Mate J 2007 Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am. J. Gastroenterol. 102: 1518-1527. *
Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J 2007 Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel Dis. 13: 1106-1114. *
Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM 2003 Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med. Clin. (Barc.) 121: 1-5.
Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM 2006 Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 53: 399-404.
Gisbert JP, Nino P, Cara C, Rodrigo L 2008 Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study on 394 patients. Aliment. Pharmacol. Ther. 28: 228-238. *
Gisbert JP, Nino P, Rodrigo L, Cara C, Guijarro LG 2006 Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am. J. Gastroenterol. 101: 2769-2776. *
Glas J, Torok HP, Daczo J, Tonenchi L, Folwaczny M, Folwaczny C 2005 The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur. J. Med. Res. 10: 535-538.
Glintborg B 2000 Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine. Ugeskr. Laeger. 162: 4553-4554.
Goerres MS, Meijer JWR, Wahab PJ, Kerckhaert JAM, Groenen PJTA, Van Krieken JHJM, Mulder CJJ 2003 Azathioprine and prednisone combination therapy in refractory Coeliac disease. Aliment. Pharmacol. Ther. 18: 487-494. *
Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF 2007 Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 13: 1365-1368.
Gogos CA, Nikolopoulou V, Zolota V, Siampi V, Vagenakis A 1999 Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J. Hepatol. 30: 321-324. *
Goh J, O'Morain CA 2003 Review article: nutrition and adult inflammatory bowel disease. Aliment. Pharmacol. Ther. 17: 307-320. *
Gohar S, Desai D, Joshi A, Bhaduri A, Deshpande R, Balkrishna C, Chawla M, Rodrigues C, Joshi VR 2003 Autoimmune hepatitis: a study of 50 patients. Indian J. Gastroenterol. 22: 140-142. *
Goldenberg BA, Rawsthorne P, Bernstein CN 2004 The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am. J. Gastroenterol. 99: 1744-1748. *
Goldenberg G, Jorizzo JL 2005 Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J. Dermatolog. Treat. 16: 347-349.
Goldstein F 1987 Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. J. Clin. Gastroenterol. 9: 654-658.
Goldstein F, Menduke H, Thornton JJ 3rd, Abramson J 1980 Anti-inflammatory drug treatment of Crohn's disease: a prospective evaluation of 100 consecutively treated patients. J. Clin. Gastroenterol. 2: 77-85.
Gomollon F 2006 Treatment safety in inflammatory bowel disease. Gastroenterol. Hepatol. 29 Suppl. 3: 45-51.
Gomollon F, Garcia Lopez S 2008 Are we giving azathioprine too much time? World J. Gastroenterol. 14: 5519-5522. *
Gomollon F, Gisbert JP, Gassull MA 2008 Crohnology: a tale of time and times and inflammatory bowel diseases. World J. Gastroenterol. 14: 5489-5490. *
Gong Y, Christensen E, Gluud C 2007 Azathioprine for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD006000. *
Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F 2005 Maintenance of remission in Crohn's disease. Digestion 71: 41-48.
Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F 2007 Maintenance of medically induced remission of Crohn's disease. Digestion 76: 116-129.
Gonzalez MG, Madrazo CP, Rodriguez AB, Gutierrez MG, Herrero JI, Pallardo JM, Ortiz de Urbina J, Paricio PP 2005 An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: a comparison of dual vs. triple drug therapy. Liver Transpl. 11: 515-524. *
Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P 2005 Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm. Bowel Dis. 11: 8-15. *
Gordon JN, Sabatino AD, Macdonald TT 2005 The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr. Opin. Gastroenterol. 21: 431-437.
Gordon RD, Shaw BW Jr, Iwatsuki S, Esquivel CO, Starzl TE 1986 Indications for liver transplantation in the cyclosporine era. Surg. Clin. North Am. 66: 541-556.
Gorson KC 2006 Therapy for vasculitic neuropathies. Curr. Treat. Options Neurol. 8: 105-117.
Gorson KC 2007 Vasculitic neuropathies: an update. Neurologist 13: 12-19.
Gossard AA, Lindor KD 2007 Development of autoimmune hepatitis in primary biliary cirrhosis. Liver Int. 27: 1086-1090. *
Goto T, Komatsu M, Fujii T, Ohshima S, Nakane K, Yoneyama K, Shibuya T, Meng XW, Masamune O, Imai H 1999 Primary biliary cirrhosis associated with membranous glomerulonephritis. Intern. Med. 38: 22-26. *
Grando SA 2004 New approaches to the treatment of pemphigus. J. Investig. Dermatol. Symp. Proc. 9: 84-91. *
Grassi M, Manzi P, Schiffino L, Raffa S 1997 Current aspects of therapy of primary biliary cirrhosis. Clin. Ter. 148: 95-104.
Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W 2003 Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12: 409-412.
Grbovic L, Radenkovic M 2005 Therapeutic use of glucocorticoids and immunosuppressive agents. Srp. Arh. Celok. Lek. 133 Suppl. 1: 67-73.
Green CJ, Mee AS 2006 Re-introduction of azathioprine in previously intolerant patients. Eur. J. Gastroenterol. Hepatol. 18: 17-19.
Greenstein RJ, Su L, Juste RA, Brown ST 2008 On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. PLoS ONE 3: e2496. *
Griffiths AM 2003 Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary. Inflamm. Bowel Dis. 9: 389-391. *
Griffiths AM 2005 Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con. Inflamm. Bowel Dis. 11: 200-202. *
Grogan PM, Katz JS 2004 Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161.
Grootscholten C, Bajema IM, Florquin S, Steenbergen EJ, Peutz-Kootstra CJ, Goldschmeding R, Bijl M, Hagen EC, Van Houwelingen HC, Derksen RH, Berden JH 2007 Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum. 56: 924-937. *
Grootscholten C, Dieker JW, McGrath FD, Roos A, Derksen RH, van der Vlag J, Daha MR, Berden JH 2007 A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann. Rheum. Dis. 66: 693-696. *
Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, Derksen RH, Berden JH 2006 Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 70: 732-742. *
Grossman AB, Noble AJ, Mamula P, Baldassano RN 2008 Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm. Bowel Dis. 14: 750-755.
Gundling F, Rohrbach H, Schepp W 2007 Cholestatic hepatitis in situs inversus abdominalis. Schweiz. Rundsch. Med. Prax. 96: 1029-1033.
Gupta G, Lautenbach E, Lewis JD 2006 Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 1483-1490.
Gupta N, Bostrom AG, Kirschner BS, Cohen SA, Abramson O, Ferry GD, Gold BD, Winter HS, Baldassano RN, Smith T, Heyman MB 2008 Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am. J. Gastroenterol. 103: 2092-2098.
Gurel S, Kiyici M 2005 Ulcerative colitis activity index: a useful prognostic factor for predicting ulcerative colitis outcome. J. Int. Med. Res. 33: 103-110.
Gutkowski K, Bilkiewicz T 2006 Experimental methods in the treatment of Lesniowski-Crohn disease. Pol. Merkuriusz. Lek. 20: 457-461.
Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G 2003 Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment. Pharmacol. Ther. 18: 33-44. *
Haglund S, Taipalensuu J, Peterson C, Almer S 2008 IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol. 65: 69-77. *
Hagymasi K, Tulassay Z 2005 Pharmacogenetics of inflammatory bowel disease. Orv. Hetil. 146: 1143-1150.
Hait EJ, Bousvaros A, Schuman M, Shamberger RC, Lillehei CW 2007 Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J. Pediatr. Surg. 42: 31-34.
Hakem D, Berrah A, Berkane S, Asselah H, Ait-Younes S, Asselah F, Salah S, Merriche S, Abbadi MC 2005 Autoimmune chronic active hepatitis: anatomoclinic's study of 50 patients. Rev. Med. Interne. 26: 858-865.
Halverstam CP, Lebwohl M 2008 Nonstandard and off-label therapies for psoriasis. Clin. Dermatol. 26: 546-553.
Hamburg SM, Piers DA, van den Berg AP, Slooff MJ, Haagsma EB 2000 Bone mineral density in the long term after liver transplantation. Osteoporos. Int. 11: 600-606. *
Hamnik SE, Hacein-Bey L, Biller J, Gruener G, Jay W 2008 Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations. Semin. Ophthalmol. 23: 191-200.
Hanada H, Okita K 1994 Primary biliary cirrhosis: therapy and prognosis. Nippon Rinsho 52: 256-261.
Hanauer SB 2004 The long-term management of ulcerative colitis. Aliment. Pharmacol. Ther. 20 Suppl. 4: 97-101. *
Hanauer SB 2004 Optimal approach to perianal Crohn's disease. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 75. May 7-8. *
Hanauer SB 1999 Medical therapy for Crohn's disease. Curr. Opin. Gastroenterol. 15: 308.
Hanauer SB 2005 A BALANCING VIEW: lifetime channeling of infliximab for Crohn's disease. Am. J. Gastroenterol. 100: 1438-1439. *
Hanauer SB 2003 Assessing the risk of lymphomas in inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 50-51. *
Hanauer SB, Present DH 2003 The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 81-92. *
Handa R 2003 Spondylo-arthropathies. J. Indian Med. Assoc. 101: 514, 516, 518.
Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S 2006 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm. Bowel Dis. 12: 251-257. *
Harboe E, Goransson L, Wildhagen K, Omdal R 2005 Mycophenolate mofetil: a new therapeutic agent for chronic autoimmune diseases. Tidsskr. Nor. Laegeforen. 125: 1650-1652.
Harloff S, Hartwig D, Kasper K, Wedel T, Muller M, Geerling G 2008 Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis. Klin. Monatsbl. Augenheilkd. 225: 200-206.
Hart AL, Plamondon S, Kamm MA 2007 Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized con